BY David M. Gershenson, M.D.

The Holy Grail of oncology is personalized cancer therapy. While patients with either malignant ovarian germ cell tumors or ovarian sex cord-stromal tumors, constituting two of the three major categories of ovarian cancer, have historically been treated on separate clinical trials, women with all types of epithelial tumors have been treated identically on the same trials over the past several decades.

With the explosion of information...